Table 1. Assessment protocol for the current study from V1 to V6.
| Visit of data entry | V1 | V2 | V3 | V4 | V5 | V6 |
|---|---|---|---|---|---|---|
| Meets enrolment/exclusion criteria | X | |||||
| Month | 1 | 3 | 6 | 9 | 12 | |
| Days | X | 30 (± 7) days after first injection | 90 (±7) days after first injection | 180 (±7) days after first injection | 270 (±7) days after first injection | 360 (±7) days after first injection |
| Consent form | X | |||||
| Demographic data | X | |||||
| Systemic and ocular disease history | X | |||||
| BCVA | X | X | X | X | X | X |
| IOP | X | X | X | X | X | X |
| OCT | X | X | X | X | X | X |
| OCTA | X | X | X | X | X | X |
| AO fundus camera | X | X | X | X | X | X |
| mfERG | X | X | X | X | X | X |
| Microperimetry | X | X | X | X | X | X |
| Serum vitamin B12 | X | X | X | X | X | X |
| Accompanying medication | X | X | X | X | X | X |
| Data record | X | X | X | X | X | X |
| Treatment programme records | X | X | X | X | X | |
| Adverse events | X | X | X | X | X | |
| Serious adverse events | X | X | X | X | X |
AO, adaptive optic; BCVA, best-corrected visual acuit; IOP, intraocular pressure; mfERG, multifocal electroretinography; OCT, optical coherence tomography; OCTA, optical coherence tomography angiography.